Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Genetic Technologies Limited (GTG.AX) specializes in genetic testing and diagnostics, focusing on risk assessment for various health conditions, particularly in oncology. The company operates primarily in Australia and the United States, leveraging its proprietary genetic algorithms to provide personalized healthcare solutions.
GTG generates revenue primarily through genetic testing services, which are priced based on the complexity and type of tests conducted. The company has a competitive advantage through its proprietary algorithms that enhance the accuracy of risk assessments, allowing for better patient outcomes and potentially higher reimbursement rates from insurers.
Regulatory approvals for new genetic tests
Partnerships with healthcare providers for testing services
Advancements in genetic research impacting product offerings
Market adoption rates of genetic testing in oncology
Regulatory changes affecting genetic testing approvals
Technological disruption from competitors developing superior testing methods
Emergence of new players in the genetic testing market
Price competition from established diagnostic companies
Negative operating cash flow impacting liquidity
High operating margin loss leading to potential solvency concerns
moderate - The demand for genetic testing can be influenced by overall healthcare spending, which is correlated with GDP growth.
Interest rates affect GTG's financing costs for R&D and operational expenses, potentially impacting its ability to invest in growth initiatives.
minimal - The company's debt levels are manageable, and it has a current ratio of 0.88, indicating sufficient liquidity.
growth - Investors looking for exposure to innovative healthcare solutions and genetic testing advancements.
high - The stock has shown significant volatility with a 1-year return of -80.5%, indicating potential for sharp price movements.